DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...

In a report released today, Richard Newitter from Truist Financial reiterated a Buy rating on Dexcom, with a price target of $80.00. Claim 55% Off TipRanks. Unlock hedge fund-leve ...

In a report released today, Brandon Vazquez from William Blair maintained a Buy rating on Dexcom, with a price target of $59.00. According to TipRanks, Vazquez is an analyst with an average return of ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...

Event context and recent share performance DexCom (DXCM) shares have been under pressure recently, with the stock down about 3% over the past month and 8.6% over the past 3 months, while the business ...

DexCom, Inc. reported past first-quarter 2026 results with revenue of US$1,191.9 million, net income of US$199.5 million, and diluted EPS of US$0.51, while reaffirming full-year revenue guidance of ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong fourth-quarter 2024 performance and a series of favorable coverage decisions are ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

Is DXCM a good stock to buy? We came across a bullish thesis on DexCom, Inc. on Part-Time Compounder’s Substack by Francesco ...

DexCom (NASDAQ:DXCM) stock experienced a significant 16% surge on Friday following its Q1 earnings release and a share buyback announcement. The company’s first-quarter sales reached $1.04 billion, ...

DexCom (DXCM) delivered earnings and revenue surprises of +19.66% and +1.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market close. Here’s what ...